CVS Health (NYSE: CVS) Reinstates Zepbound Coverage And Adds New Weight-Loss Pill To Drug Plans

CVS Health (NYSE: CVS) announced it will reinstate coverage of Eli Lilly’s weight-loss injectable Zepbound and begin covering the anti-obesity pill Foundayo for millions of Americans on private insurance plans.

CVS Health (NYSE: CVS) Reinstates Zepbound Coverage And Adds New Weight-Loss Pill To Drug Plans. CVS Health (NYSE: CVS) announced it will reinstate coverage of Eli Lilly’s weight-loss injectable Zepbound and begin covering the anti-obesity pill Foundayo for millions of Americans on private insurance plans. Coverage of Zepbound will begin Oct. 1, while coverage of Lilly’s weight-loss pill Foundayo will start June 1 under the move. Both drugs will appear on the standard template from CVS Caremark, a prescription drug manager used by insurers and employers serving millions of Americans. A year ago, CVS Caremark struck a deal to make Novo Nordisk’s anti-obesity drug Wegovy a preferred GLP-1 medication without extending similar status to Zepbound. Wegovy, now sold as both an injectable and a weight-loss pill, will remain on CVS Caremark’s stan...